Immunocal Testimonials #139 – Professor Dr. Wulf Droge

Professor Dr. Wulf Droge, Immunologist and former head of Cancer Research at the Heidelberg Cancer Institute, Heidelberg, Germany

Professor Wulf Droge is now Medical Director of Immunotec Research in charge of research with Immunocal.

The human immune system is extremely dependent on adequate glutathione levels to perform properly, in the words of Wulf Droge et. al. : “Thiols And The Immune System: Effect of N-Acetyl cysteine on T Cell System in Human Subjects”; Methods in Enzymology, Vol. 251; 255-270,1995):

“Even a partial depletion of the intracellular glutathione pool has a dramatic consequence for the process of blast transformation and proliferation, and for the generation of cytotoxic T cells.” ( T –cells are those cells which help the body defend against diseases.)

Abstract: – Cysteine and glutathione in catabolic conditions and immunological dysfunction. Current Opinion in Clinical Nutrition &

Metabolic Care. 2(3):227-233, May 1999. Droge, Wulf

The conspicuous increase in the plasma cysteine disulphide/thiol ratio in elderly persons and cancer patients indicates a shift of the plasma redox state.

The most important redox buffers in skeletal muscle tissue and blood plasma, i.e. glutathione and albumin, respectively, are significantly decreased in different models of cachexia. Treatment with N-acetyl cysteine, i.e. a thiol-containing antioxidant, was found to increase the plasma albumin level and to ameliorate the loss of body cell mass in cancer patients and healthy individuals. The treatment of HIV infection with N-acetyl cysteine, in contrast, serves mainly as a tool to ameliorate the physiological and immunological consequences of the virus-induced cysteine deficiency. NOTE: Immunocal, a natural cysteine delivery system, developed and researched at McGill University Medical Research Center (often referred to by Doctors in the USA as “The Harvard of the North” in Montreal, Canada, was found to increase glutathione and the plasma albumin levels in vitro, in animal and human studies.

Dr. Wulf Droge is now Medical Director of Immunotec Research’s Medical Advisory Board, in charge of research with Immunocal. Here is a list of his ACADEMIC CREDENTIALS:

1958 – 1964 Studied chemistry and biochemistry at the Universities of Hanover and Freiburg, Germany Master’s degree in chemistry

1964 – 1967 PH.D. thesis at the Max-Planck-Institute of Immunology, Freiburg (topic of thesis, Bacterial Lipopolysaccharides)

1967 PH.D. in biochemistry, University of Freiburg postdoctoral DFG fellowship at the Max-Planck- Institute of Immunology, Freiburg

1968 Visiting fellow at the University of Minnesota, Minneapolis

1968-1971 Postdoctoral research fellow at Harvard University,Biological Laboratories, Cambridge, Mass. with professor Strominger

1971-72 Fellow at the Max-Planck-Institute in Munchan, Germany

1973-76 Scientific member at the Basel Institute for Immunology

1974 Habilitation at University of Freiburg

Since 1976 Professor, faculty of Biology at the University of Heidelburg and head of the Department of Immunochemistry

RESEARCH AREAS:

  • Redox regulation and signaling pathways in lymphocytes
  • Pathogenesis of HIV infection
  • Mechanism of disease related wasting and aging
  • Action of tumor necrosis factor
  • 1977-1980- and 1983-1986- Acting Director of the Institute of Immunology and Genetics, Heidelburg, Germany

MEMBERSHIPS:

  • European Association for Cancer Research
  • American Association of Immunologists
  • British Society of Immunology
  • Gesellschaft fur Immunologie

 

This entry was posted in Immunocal Testimonials and tagged , . Bookmark the permalink.